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Aims:To test the hypothesis that patientswith nocturia owing to diminished global or
nocturnal bladder capacity improve via increased bladder capacity.
Methods: This is a retrospective analysis of voiding diaries completed at a VA
urology clinic between 2008–2017. Inclusion required patients aged at least 18 years,
male, undergoing treatment for nocturia, and having completed at least two 24-hour
voiding diaries ≥1 month apart. Patients were divided into two cohorts: responders
(any decline in nocturia) and non-responders (no change or any increase in nocturia).
Patients were further sub-stratified as having low global bladder capacity (maximum
voided volume [MVV] <200 mL) versus low nocturnal bladder capacity (nocturnal
maximum voided volume [NMVV] <200 mL and MVV ≥200 mL). Wilcoxon rank-
sum was applied with a Bonferroni correction to test significance.
Results: Forty pre- and post-treatment diaries from 27 patients, and 19 pre- and post-
treatment diaries from 17 patients were identified as having low global and low
nocturnal bladder capacity, respectively. Nocturia responders with low global
bladder capacity demonstrated significant decline compared to non-responders in
nocturnal urine volume (NUV) (−140 vs +75, P< 0.01) and nocturnal bladder
capacity index (NBCi) (−0.59 vs +0.23, P< 0.01). Patients with low nocturnal
bladder capacity similarly demonstrated decreased NUV (−30 vs +160, P= 0.04)
and NBCi (−1.4 vs +0.33, P< 0.01). There was no significant change in MVV or
NMVV for either group.
Conclusions: Treatment directed at lowering nocturnal urine production and
enabling patients to consistently void at capacity is a rational strategy to treat nocturia




Nocturia, defined as voiding that occurs during the hours of
intended sleep, is among the most common urological
conditions in the general population.1 Older patients are
particularly affected, with an estimated 56% of males aged
75 years or older reporting symptoms of nocturia in the
National Health and Nutrition Examination Survey
(NHANES).2 Several studies have demonstrated nocturia to
be associated with both increased mortality and a lower
quality of life.3–5
The cause of nocturia is often complex, and management
is predicated on identifying the specific mechanism
David Ginsberg led the peer-review process as the Associate Editor
responsible for the paper.
Neurourology and Urodynamics. 2019;38:215–222. wileyonlinelibrary.com/journal/nau © 2018 Wiley Periodicals, Inc. | 215
underlying a patient's symptoms. One cause of nocturia is
diminished bladder capacity, which may be present through-
out the day (global), or only during the hours of intended sleep
(nocturnal).6 In either case, nocturnal voiding is driven by
nocturnal urine volume in excess of nocturnal urine storage
capacity.6 Diminished bladder capacity among older men has
many urological causes, among the most common being
prostatic obstruction, which results in a weaker urinary flow
and thus poor bladder emptying.7
Management of nocturia owing to low capacity bladder
may include behavioral techniques such as restricted fluid
intake, bladder training, urge suppression, and pelvic floor
exercises; pharmacotherapy with α-adrenergic antagonists,
antimuscarinics, or β3-adrenergic agonists; or more invasive
interventions, such as trans-urethral resection of the prostate
(TURP), neuromodulation or botulinum toxin detrusor
muscle injections.8–10
Although the urologist's toolkit continues to expand,
clinical drug trials have shown statistically significant—but
clinically equivocal—outcomes, and real-world observa-
tional studies have likewise demonstrated poor efficacy of
treatment directed at nocturia owing to diminished bladder
capacity.11–15 As such, an effective standard management
strategy for the treatment of nocturia due to low capacity
bladder has yet to be identified.
The 24-hour voiding diary is a valuable resource in the
clinical evaluation of nocturia.6 Diary analysis can be used
initially for diagnosis of nocturia owing to small capacity
bladders, subsequently to evaluate a patient's response to
treatment. and to provide patients with feedback to reinforce
behaviors that lead to improvement in nocturia severity. The
overall aim of this responder analysis study is to identify
mechanisms that underlie nocturia improvement in men with
a small capacity bladder. Specifically, we seek to test the
hypothesis that patients whose nocturia is primarily due to
small capacity bladder improve as a result of increased
bladder capacity.
2 | MATERIALS AND METHODS
2.1 | Patients
A database of 749 voiding diaries completed by 425 patients
from a Veterans Affairs-based urology clinic seeking
treatment for lower urinary tract symptoms (LUTS) was
retrospectively analyzed. Included were male patients aged
18 years or older who had a baseline voiding diary showing at
least 1 nocturic episode and completed a follow-up diary 30 or
more days after the baseline diary. Voiding diaries with
incomplete data were not included. Of the initial set, 466
voiding diaries from 124 patients met the inclusion criteria.
Table 1 provides an overview of patient demographics,
including age, race, comorbidities, baseline α-adrenergic
blocker status, urological surgery history, and radiation
TABLE 1 Baseline characteristics of patients with low capacity bladder
Low global bladder capacity Low nocturnal bladder capacity
Responder (n= 11) Non-responder (n= 16) Responder (n= 7) Non-responder (n= 10)
Age 67 (52-82) 70 (60-80) 74 (68-81) 72 (53-91)
Ethnicity
Caucasian 4 (36.4) 5 (31.2) 2 (28.6) 6 (60)
African-American 6 (54.5) 9 (56.2) 4 (57.1) 2 (20)
Other/unknown 1 (9.1) 2 (12.5) 1 (14.3) 2 (20)
Comorbidities
Hypertension 7 (63.6) 11 (68.8) 4 (57.1) 7 (70)
Diabetes 0 (0) 2 (12.5) 2 (28.6) 0 (0)
Sleep apnea 2 (18.2) 1 (6.2) 1 (14.3) 0 (0)
Medication
α-blocker 9 (81.8) 10 (62.5) 4 (57.1) 8 (80)
Surgery
RRP 0 (0) 0 (0) 0 (0) 0 (0)
TURP 0 (0.0) 1 (6.2) 2 (28.6) 1 (10)
Urethroplasty 1 (9.1) 0 (0) 0 (0) 0 (0)
Radiation
EBRT 1 (9.1) 0 (0) 0 (0) 0 (0)
Brachytherapy 0 (0) 1 (6.2) 0 (0) 0 (0)
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history. For demographic data, categorical variables are
reported as frequency (proportion), and continuous variables
are reported as median (interquartile range).
2.2 | Study design and procedures
Data for this study were obtained from a real-world setting,
whereby patients seeking treatment at a urology clinic were
asked to complete paper voiding diaries as per best practice
standards in the diagnosis and evaluation of LUTS.10 Patients
were managed according to the framework depicted in
Figure 1. Initially, patients were managed with behavioral
advice (drinking fluids only as needed for thirst and/or
bladder training), and, if warranted, with pharmacological
treatment utilizing anticholinergics or β3 agonists for
urgency/overactive bladder; α-blockers and/or 5-α-reductase
inhibitors for prostatic obstruction; and outlet reducing
surgery for urinary retention refractory to pharmacologic
treatment. Only a single intervention (ie, start of new
medication or change of dose) was implemented at each
visit to effectively assess response to treatment. This study
was not powered to determine a treatment effect for a specific
treatment, but rather to investigate the physiological mecha-
nisms relating to how patients saw improvement.
Patients were divided into two cohorts: responders (178
diaries [89 pre- and post-treatment] from55 patients), defined as
a decline of at least one nocturic episode between two
subsequent diaries, and non-responders (288 diaries [144 pre-
and post-treatment] from 69 patients), defined as having no
change or an increase in nocturia between two subsequent
diaries. Patients were further sub-stratified as having low global
bladder capacity (maximum voided volume [MVV] <200mL)
versus low nocturnal bladder capacity, (nocturnal maximum
voided volume [NMVV]<200mL andMVV≥200mL). There
is no standard definition of low capacity bladder from voiding
diaries, so a cut-off of 200mLwas chosen forMVVandNMVV
FIGURE 1 Flow chart of study design. Row 1 begins with a patient with nocturia defined by ANV≥ 1. Row 2 divided patients by diary
information, where maximum voided volume (MVV) < 200 indicates reduced bladder capacity, and nocturnal polyuria index (NPi) > 0.33
indicates nocturnal polyuria. Row 3 further subdivides theetiology into treatable conditions. Row 4 demonstrates the treatment used for nocturia
etiologies
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because this approximates the lower standard deviation ofMVV
in populations studiedwith conditions predisposing them to low
bladder capacity, and is below lower capacities observed in
asymptomatic patients.16–17
Diary parameters that were calculated from the voiding
diaries were: 24-hour urine volume, calculated as total volume
of urine produced during a 24-hour period; nocturnal urine
volume (NUV), calculated as total volume of urine passed
during the night, including the first morning void; maximum
voided volume (MVV), calculated as the largest single voided
volume in a 24-hour period; nocturnalmaximumvoided volume
(NMVV), calculated as the largest single voided volume during
the night; actual number of nighty voids (ANV), defined as the
number of voids recorded from the time the individual goes to
bed with intention of sleeping, to the time the individual wakes
with the intention of rising; nocturia index (Ni), calculated as
Ni =NUV/MVV (when Ni > 1, NUV exceeds maximum
storage capacity and nocturia or enuresis occurs); nocturnal
polyuria index (NPi), calculated as NPi =NUV/(24-hour urine
volume); nocturnal urine production (NUP), calculated as
NUP=NUV/(# hours asleep); predicted number of nightly
voids (PNV), calculated as PNV=Ni−1; nocturnal bladder
capacity index (NBCi), calculated as ANV−PNV (NBCi > 0
indicates that nocturia will occur at voided volumes <MVV.
NBCi > 2 associated with severe nocturia); first uninterrupted
sleep period (FUSP), calculated as # hours between the time the
individual goes to bed with the intention of sleeping to the time
of first awakening.
2.3 | Statistical analysis
Baseline and change from baseline values (difference
between post- and pre-treatment voiding diaries) were
calculated for all diary parameters. These values were
reported for both responders and non-responders, in both
the low global bladder capacity and low nocturnal bladder
capacity cohort. Diary parameters are reported as median
(95% confidence interval) using Wilcoxon confidence
interval estimates. Continuous and categorical parameters
were compared using unpaired Wilcoxon rank-sum tests and
the chi-square tests, respectively; Bonferroni correction was
applied for multiple comparisons. Univariate linear regres-
sion was performed on pre- to post-treatment change in
nocturia severity (ANV) and the change in all aforementioned
voiding diary parameters.
3 | RESULTS
Of the original cohort, 59 baseline diaries from 44 patients
met criteria for either low global or nocturnal capacity
bladder, representing 25% of the original cohort of diaries
(35% of patients). In the low global bladder capacity cohort,
40 diaries were completed at the pre-treatment (baseline)
visit, and 40 were completed at the post-treatment visit. In the
low nocturnal bladder capacity cohort, 19 diaries were
completed at the pre-treatment (baseline) visit, and 19 were
completed at the post-treatment visit. Baseline voiding
parameters in responders were compared to non-responders;
low global bladder capacity demonstrated a large difference
in ANV (4 vs 2, respectively; P= 0.011). Slightly more than
half of the cohort with low global bladder capacity also had
nocturnal polyuria (NPi > 0.33) at baseline (22 diaries, 55%).
Five patients (26%) with low nocturnal bladder capacity had
nocturnal polyuria at baseline. No differences were seen in
baseline voiding parameters in responders compared to non-
responders in patients with low nocturnal bladder capacity.
An overview of these results is provided in Table 2.
TABLE 2 Baseline voiding diary parameters for responders versus non-responders with low global or low nocturnal bladder capacity
Low global bladder capacity Low nocturnal bladder capacity
Responder (n= 13) Non-responder (n= 27) P-val Responder (n= 7) Non-responder (n= 12) P-val
24 h volume 1100 (870-1500) 1100 (1000-1300) 1 1300 (1200-2000) 1400 (1300-1800) 1
Voids in 24 h 12 (10-15) 12 (10-13) 1 10 (9-13) 10 (9-12) 1
ANV 4 (3-5) 2 (2-3) 0.011 2 (1.5-4) 1.5 (1-2.5) 1
MVV 150 (120-180) 180 (140-170) 1 240 (220-350) 230 (210-320) 1
NBCi 1.3 (1-3) 0.64 (0.65-1.2) 0.19 1.7 (1.1-2.9) 1.1 (0.78-1.4) 0.69
Ni 3.1 (2.4-4.3) 2.5 (2.2-2.8) 1 1.2 (0.75-2.7) 1.6 (1.2-2.2) 1
NMVV 150 (92-160) 150 (120-160) 1 180 (150-180) 140 (120-170) 1
NPi 0.38 (0.31-0.55) 0.33 (0.3-0.38) 1 0.22 (0.18-0.43) 0.27 (0.21-0.35) 1
NUP 64 (47-78) 47 (42-56) 1 49 (27-69) 50 (43-70) 1
NUV 540 (350-690) 380 (330-440) 1 420 (220-580) 410 (320-540) 1
Low global bladder capacity =MVV< 200mL; Low nocturnal bladder capacity = NMVV< 200 mL; and MVV≥ 200 mL. ANV, actual nocturnal voids; MVV,
maximum voided volume; NBCi, nocturnal bladder capacity index; Ni, nocturia index; NMVV, nocturnal maximum voided volume; NPi, nocturnal polyuria index; NUP,
nocturnal urine production; NUV, nocturnal urine volume.
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Patient characteristics were compared between patients
in the low global bladder capacity group and those with the
low nocturnal bladder capacity, which included age (68 vs
74 years, respectively), ethnicity (33 vs 47% white; 56 vs
35% African-American), comorbidities (67 vs 65% hyper-
tension, 7 vs 12% diabetes mellitus, 11 vs 6% sleep apnea),
baseline α-blocker status (70 vs 71%), urologic surgery (0
vs 0 radical retropubic prostatectomy, 4 vs 18% trans-
urethral resection of prostate, 4 vs 0% urethroplasty), and
radiation (4 vs 0% external beam radiation therapy, 4 vs 0%
brachytherapy). Further breakdown of demographics in
cohorts between responders and non-responders is reported
in Table 1.
The change in patients with low global bladder capacity
from baseline in responders compared with non-responders,
respectively, revealed significant differences in NBCi (−0.59
vs +0.23; P< 0.01), Ni (−1.1 vs +0.24; P< 0.01), NPi
(−0.082 vs +0.048; P< 0.01), NUP (−8.4 vs +10 mL/h;
P= 0.02) and NUV (−140 vs +75 mL; P< 0.01). Significant
differences were seen in the change from baseline among
patients with low nocturnal bladder capacity in NUV (−30 vs
+160 mL; P= 0.04) and NBCi (−1.4 vs +0.33; P< 0.01) in
responders compared to non-responders, respectively. These
results are further detailed in Table 3.
To quantify the effects of these relationships, a univariate
linear regressionwas performed on the different voiding diary
parameters as a function of change in nocturia severity
(Table 4). Notably, MVV, and NMVV had no significant
relationship in patients with either low global or low nocturnal
bladder capacity. Additionally, the regression between ANV
and 24 h was found to be significant for patients with low
nocturnal bladder capacity (slope coefficient = 1.6E3;
P< 0.001), but not significant in patients with low global
bladder capacity (slope coefficient = 2.8E5; P= 0.9).
4 | DISCUSSION
To date, few investigations have utilized voiding diaries to
examine the mechanism of treatment response. Therefore,
this examination of the mechanisms by which patients with a
low capacity bladder respond to nocturia treatment reflects a
novel investigative utility of voiding diaries. Patients with
low global bladder capacity achieved relief of their nocturia
symptoms through four mechanisms:
1). Patients who responded tended to drink less. This is
reflected in decreased 24-hour urine volume. Fluid
restriction is already an accepted method of achieving
improvement in nocturia severity; this study provides
additional evidence to seek means to diminish nocturnal
urine output in patients with low capacity bladders—
whether or not nocturnal polyuria is present.11,18 Notably,
fluid restriction should be implemented safely in patients
more susceptible to dehydration, and particular care must
be taken when treating the elderly, who have a decreased
thirst response to dehydration and can less reliably self-
regulate hydration.19–21 Lowering nocturnal urine pro-
duction is a rational strategy to treat nocturia in patients
with low bladder capacity despite the absence of nocturnal
polyuria.
2). Patients who improved had diminished nocturnal urine
production compared to their pre-treatment visit (re-
flected in decreased NUV and NUP). This indicates that
TABLE 3 Change from baseline voiding diary parameters for responders versus non-responders with low global or low nocturnal bladder capacity








24 h volume −130 (−460-45) 66 (−85-180) 0.72 −120 (−400-72) 75 (25-300) 0.11
Voids in
24 h
−2 (−3.5-−1) 0 (−1-1) 0.059 −1 (−3.5-7.8e-05) 1 (4.5e-05-2) 0.084
ANV −2 (−2.5-−1.5) 0 (1-2) <0.01 −1 (−2-−1) 1 (1-2.5) <0.01
MVV 0 (−38-41) −2.5 (−25-29) 1 0 (−60-65) 7.5 (−7.5-48) 1
NBCi −0.59 (−1.4-−0.3) 0.23 (0.093-0.57) <0.01 −1.4 (−1.6-−0.82) 0.33 (0.16-0.73) <0.01
Ni −1.1 (−1.4-−0.69) 0.24 (0.11-0.63) <0.01 −0.24 (−0.95-0.12) 0.37 (0.15-0.83) 0.055
NMVV −7.5 (−70-45) 0 (−20-32) 1 0 (−140-73) 40 (5e-05-75) 1
NPi −0.082 (−0.14-−0.043) 0.048 (0.0056-0.083) <0.01 −0.045 (−0.087-0.051) 0.039 (0.0063-0.1) 0.92
NUP −8.4 (−31-1.5) 10 (3-20) 0.02 −8.5 (−34-17) 17 (8.2-29) 0.25
NUV −140 (−290-75) 75 (35-160) <0.01 −30 (−230-65) 160 (75-250) 0.04
Low global bladder capacity =MVV< 200mL; Low nocturnal bladder capacity = NMVV< 200 mL; and MVV≥ 200 mL. ANV, actual nocturnal voids; MVV,
maximum voided volume; NBCi, nocturnal bladder capacity index; Ni, nocturia index; NMVV, nocturnal maximum voided volume; NPi, nocturnal polyuria index; NUP,
nocturnal urine production; NUV, nocturnal urine volume.
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patients were producing less urine at night, which can be
explained by a decrease in nocturnal fluid intake, or
through reduced natriuresis or greater free water
reabsorption (as might be mediated by arginine
vasopressin).
3). Responders experienced closer alignment of nocturnal
urine volume with bladder capacity (reflected in
decreased Ni). This is likely due mainly to decreased
nocturnal urine volume, as maximum voided volume did
not change.
4). Responders experienced no increase in bladder capacity
compared to non-responders, but rather had an increased
tendency for nocturia voids to occur at volumes close to
their bladder capacity (reflected in decreased NBCi).
This was perhaps themost striking finding of our analysis,
as it refutes the notion that nocturia improvement in
patients with underlying low bladder capacity comes
about via increased voided volumes.
Taken together, positive response to nocturia treatment
appears to be mediated by closer alignment of nocturnal
voided volume and bladder capacity, as well as by
minimization of fluid intake and diminished nocturnal urine
volume.
The regression analysis between ANV and low global and
nocturnal bladder capacity reveals that a decrease in 24 h
volume was associated with lower ANV in patients with low
nocturnal bladder capacity, but not in low global bladder
capacity. Whether decreased intake (and hence output) in
patients with low nocturnal (but normal global) capacity is
more effective in reducing nocturia severity than in patients
with low global capacity is an interesting observation which
warrants further investigation.
Despite the observation that global or nocturnal bladder
capacities were not significantly changed in patients whose
nocturia improved, treatment designed to promote voiding at
capacity results in improved nocturia in men with low bladder
capacity. Behavioral techniques such as bladder training,
pelvic floor exercises, and urge suppression were devised to
allow patients to void closer to capacity, and thus are likely
options for the management of patients with low capacity
bladders.22,23 In order to realize the greatest benefit in control
of nocturia, even in patients requiring treatment for urgency
and/or prostatic obstruction should be encouraged to try to
void at capacity and diminish nocturnal urine output through
an individualized treatment plan.
Unfortunately, current pharmacologic treatment options
for nocturia due to small capacity bladder are less than
encouraging. Burgio et al22 demonstrated that patients already
prescribed α-blockers who were given behavioral advice and
trained on behavioral techniques had a greater drop in
nocturia severity compared to patients prescribed oxybutynin
in the MOTIVE trial. Similar results were also seen with
behavioral modifications compared with α-blockers,23 dem-
onstrating again that behavioral techniques were superior to
pharmacological therapy. As there are currently no pharma-
cologic therapies available for increasing bladder capacity,
there exists an urgent need to identify new strategies for
increasing capacity.
There were no differences in baseline voiding parameters
between responders and non-responders with low global
bladder capacity, except for initial nocturia severity. This
mirrors previous findings of greater nocturia severity at
baseline in nocturia responders of all etiologies.11 This
finding conveys some potential implications in counseling
patients bothered by nocturia. Patients with 3-4 voids per
night are likely to see a greater improvement in symptoms and
can thus be counseled more enthusiastically about potential
improvement, whereas patients with one or two voids per
night at their initial visit should have tempered expectations of
TABLE 4 Univariate linear regression of change in nocturia severity and change in voiding diary parameters
Low global capacity (n= 40) Low nocturnal capacity (n= 19)
Slope coefficient P-val Slope coefficient P-val
24 h volume 2.8E5 (−2.0E4-2.6E4) 0.9 1.6E3 (1.2E3-2.0E3) <0.001
Voids in 24 h 0.17 (0.098-0.24) 0.022 0.3 (0.24-0.36) <0.001
MVV −1.5E3 (−3.5E3-5.0E4) 0.44 −2.6E3 (−5.2E3-0.0) 0.33
NBCi 0.95 (0.81-1.09) <0.001 1.1 (0.97-1.2) <0.001
Ni 0.96 (0.86-1.06) <0.001 1.1 (0.96-1.24) <0.001
NMVV −3.2E4 (−2.6E3-2.0E3) 0.89 2.5E3 (8.0E4-4.2E3) 0.14
NPi 7.0 (5.8-8.2) <0.001 4.6 (3.2-6.0) 0.0018
NUP 0.026 (0.020-0.032) <0.001 0.026 (0.020-0.032) <0.001
NUV 3.6E3 (3.0E3-4.2E3) <0.001 4.0E3 (3.3E3-4.5E3) <0.001
Low global bladder capacity =MVV< 200mL; Low nocturnal bladder capacity = NMVV< 200 mL; and MVV≥ 200 mL. ANV, actual nocturnal voids; MVV,
maximum voided volume; NBCi, nocturnal bladder capacity index; Ni, nocturia index; NMVV, nocturnal maximum voided volume; NPi, nocturnal polyuria index; NUP,
nocturnal urine production; NUV, nocturnal urine volume.
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symptomatic resolution. On the other hand, patients with low
nocturnal bladder capacity did not have worse nocturia
severity at their initial visit and saw a lesser response when
nocturia improved compared to patients with low global
bladder capacity (−2 vs −1). Consequently, it appears
improvement in this population cannot be predicted from
their baseline voiding diaries.
Patient demographics incorporated in this study were:
age, ethnicity, comorbidities, baseline α-blocker status,
surgical history, and radiation history. The incidence of
nocturia has been demonstrated to be different between
certain races; specifically, blacks have been shown to have a
higher incidence of nocturia than whites.2 However, it has
been determined that race is not a determining factor of
nocturia severity, which ismore related to the results from this
study.15 In contrast, existing studies have demonstrated that
hypertension, diabetes mellitus, dyslipidemia, and obesity are
associated with lower urinary tract symptoms in general, and
more specifically, nocturia and benign prostatic hyperpla-
sia.24–26 Overactive bladder is weakly linked with obesity and
diabetes mellitus.27,28 Demographic results reported herein
are not powered to draw definitive conclusions.
Limitations of this study include small sample size and
possible errors in self-reported bladder volumes.29 Single-day
voiding diaries would appear to be less reliable than diaries
spanning 3-5 days.30 The participants of this study are all
from a single VA institution treated by a single team, and the
diaries are obtained, retrospectively. Different treatments
were given according to the framework depicted in Figure 1,
and as such, different treatments would likely determine the
manner in which a patient improved (or did not improve).
Patients were managed by a single treatment per visit in order
to evaluate response to individual treatments; however, a
multi-treatment approach at the initial visit may be a
beneficial approach which was not addressed by this study.
Some diary responses are taken from the same patient
receiving a different treatment, and thus may add bias to the
results.
5 | CONCLUSIONS
Patients with nocturia caused by low global bladder capacity
had worse nocturia severity at baseline, and improved
outcomes by decreasing nocturnal urine volume likely
through both reduced fluid intake and voiding at volumes
closer to capacity, even if increases in overall bladder
capacity is not feasible. Whether methods of modifying
nocturnal urine production through use of desmopressin,
timed diuretics, continuous positive airway pressure (in sleep
apnea patients), or antihypertensive medication for non-
dipping nocturnal blood pressure remains to be seen and
justify future investigative efforts.31–37
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